Answers are grounded in this paper and cite their sources.
The novel non-conventional metallodrug [(η6-p-cymene)2Ru2mitoxantronato]Cl2 (1) exhibits redox activity, DNA intercalation ability, cathepsin B and D inhibition and in vitro antitumor activity able to circumvent cisplatin resistance. Moreover, 1 can be successfully incorporated into MIL100(Fe) as a proof of concept of the feasibility of metal–organic frameworks as carriers of non-conventional drugs.
No takes yet. Share an insight, caveat, or question.
Rojas et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: